Edgewise Q1 net loss $28.5M; sevasemten shows positive Becker data

Edgewise Therapeutics, Inc.

2024-Q1 EPS reported -$0.33

Cash, cash equivalents and marketable securities $532.8M as of March 31, 2024.
Net loss $28.5M ($0.33 per share) vs $30.1M ($0.47) prior quarter.
Sevasemten ARCH 2-year: NSAA stabilized, CK and TNNI2 decreased; DUNE showed 45% CK reduction vs placebo.
GRAND CANYON pivotal cohort recruiting ~120 patients with Becker; data expected Q4 2024.
EDG-7500 Phase 2 CIRRUS-HCM trial initiated; first patient dosed April 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Edgewise Therapeutics, Inc. reported financial results for first quarter of 2024.

Period: first quarter of 2024
Result: reported results

Exact text from the filing

On May 9, 2024, Edgewise Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Edgewise Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-059136

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.